ETFs & MarketsBasicMonopar Therapeutics NDA Filing Sparks $125 Price Target Adjustment
H.C. Wainwright has revised its outlook on Monopar Therapeutics following a significant regulatory milestone. The firm increased its price target to $125, citing the company's recent New Drug Application filing as a primary catalyst for potential valuation shifts.
Published 1 hour ago
Read more →